- Home
- EDF vs CRDF Comparison
EDF vs CRDF Comparison
Compare EDF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- CRDF
- Stock Information
- Founded
- EDF 2010
- CRDF 1999
- Country
- EDF United States
- CRDF United States
- Employees
- EDF N/A
- CRDF N/A
- Industry
- EDF Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- CRDF Health Care
- Exchange
- EDF Nasdaq
- CRDF Nasdaq
- Market Cap
- EDF 160.2M
- CRDF 152.3M
- IPO Year
- EDF N/A
- CRDF N/A
- Fundamental
- Price
- EDF $4.92
- CRDF $2.13
- Analyst Decision
- EDF
- CRDF Strong Buy
- Analyst Count
- EDF 0
- CRDF 5
- Target Price
- EDF N/A
- CRDF $11.10
- AVG Volume (30 Days)
- EDF 160.6K
- CRDF 728.8K
- Earning Date
- EDF 01-01-0001
- CRDF 10-29-2025
- Dividend Yield
- EDF 13.14%
- CRDF N/A
- EPS Growth
- EDF N/A
- CRDF N/A
- EPS
- EDF N/A
- CRDF N/A
- Revenue
- EDF N/A
- CRDF $545,000.00
- Revenue This Year
- EDF N/A
- CRDF N/A
- Revenue Next Year
- EDF N/A
- CRDF N/A
- P/E Ratio
- EDF N/A
- CRDF N/A
- Revenue Growth
- EDF N/A
- CRDF N/A
- 52 Week Low
- EDF $3.51
- CRDF $1.90
- 52 Week High
- EDF $5.50
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- EDF 42.16
- CRDF 43.20
- Support Level
- EDF $4.93
- CRDF $2.20
- Resistance Level
- EDF $5.00
- CRDF $2.36
- Average True Range (ATR)
- EDF 0.06
- CRDF 0.11
- MACD
- EDF 0.00
- CRDF -0.01
- Stochastic Oscillator
- EDF 40.00
- CRDF 22.97
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.